LTRN · Lantern Pharma Inc.

Lantern Pharma’s 8-K filing outlines strong operational progress across its clinical pipeline and AI platforms alongside its 2025 full year and fourth quarter financial results, marking a year of key validation for its AI-driven precision oncology strategy. Management noted 2025 operating expenses fell 19% year-over-year even as the company advanced multiple programs through critical clinical milestones, highlighting disciplined capital allocation. Clinically, the LP-300 Phase 2 HARMONIC trial for never-smoker NSCLC continues to progress, with Japan enrollment completed ahead of schedule, preliminary data presented at the Japan Lung Cancer Society, and a Type C FDA meeting scheduled for mid-May 2026 to discuss protocol amendments that could streamline the trial and focus on the highest responder subgroup. The LP-184 program hit a major milestone with Phase 1a completion, meeting all primary endpoints and posting a 48% clinical benefit rate at therapeutic doses, with multiple Phase 1b/2 trials planned across hard-to-treat cancer indications. The FDA clearance of the STAR-001 IND for pediatric CNS cancers creates potential access to priority review vouchers that could generate significant non-dilutive value, while the LP-284 program added an additional Orphan Drug Designation for soft tissue sarcomas. On the commercial AI front, the launch of the withZeta.ai multi-agentic co-scientist platform, currently in beta with over 25 industry partners, positions the company to capture near-term recurring revenue from its AI capabilities beyond its drug pipeline.